Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC pediculicide drug products final monograph

This article was originally published in The Tan Sheet

Executive Summary

Amended to clarify that labeling for OTC lice treatments containing active ingredient pyrethrum extract should "provide a specified concentration range of pyrethrins in a formulated product," FDA announces in the Aug. 13 Federal Register. The final monograph is revised to read: "The active ingredients of the product consist of the combination of pyrethrum extract (providing a concentration of pyrethrins of .17% to .33%) with piperonyl butoxide (2% to 4%) in a non-aerosol dosage formulation." Previously, the monograph had said "pyrethrum extract (.17% to .33%)." The change was requested by NDMA in October 1996. FDA published the OTC pediculicide final monograph in December 1993...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel